MK-886 is an inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes).

MK-886 is an inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes).

MK-0359 is a selective and potent oral PDE4 inhibitor, in chronic asthma.

MK-0359 is a selective and potent oral PDE4 inhibitor, in chronic asthma.

MK-0359 is a selective and potent oral PDE4 inhibitor, in chronic asthma.

MK-0591 is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor with an IC50 value of 1.6 nM in a FLAP binding assay.

MK-0591 is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor with an IC50 value of 1.6 nM in a FLAP binding assay.

MK-0591 is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor with an IC50 value of 1.6 nM in a FLAP binding assay.

MK-0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated.

MK-0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated.

MK-0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated.

MK-0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated.

MK-0773, one of selective androgen receptor modulators (SARMs), is a 4-aza-steroid that exhibited tissue selectivity in humans (IC50= 6.6 nM).

MK-0773, one of selective androgen receptor modulators (SARMs), is a 4-aza-steroid that exhibited tissue selectivity in humans (IC50= 6.6 nM).

MK-0773, one of selective androgen receptor modulators (SARMs), is a 4-aza-steroid that exhibited tissue selectivity in humans (IC50= 6.6 nM).

MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models.

MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models.

MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models.

MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models.

MK-0974 (Telcagepant) is a potent and selective antagonist of the human and rhesus CGRP receptors.

MK-0974 (Telcagepant) is a potent and selective antagonist of the human and rhesus CGRP receptors.

MK-0974 (Telcagepant) is a potent and selective antagonist of the human and rhesus CGRP receptors.

MK-0974 (Telcagepant) is a potent and selective antagonist of the human and rhesus CGRP receptors.

MK-1439 is a non-nucleoside reverse transcriptase inhibitor

MK-1439 is a non-nucleoside reverse transcriptase inhibitor

MK-1439 is a non-nucleoside reverse transcriptase inhibitor

MK-1439 is a non-nucleoside reverse transcriptase inhibitor

MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.

MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.

MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.

MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.

MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection.

MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection.

MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection.

MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection.

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively.

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively.

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively.